Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: Doug Bean who wrote (1479)	11/3/1999 9:50:00 AM
From: harkenman	Read Replies (1) \| Respond to of 1837

The apporval of generics for OrtoCept/Desogen; Estropipate; Cenestin sure points out that we will reap benefits once sales start triggering. The Solvay investment will help a lot to fund the roll out to markets. I smell a winner!

To: Doug Bean who wrote (1479)	11/3/1999 12:43:00 PM
From: Richaaard	Read Replies (1) \| Respond to of 1837

I wonder if this WLA/AHP merger could play into DRMD's future? Premarin was described today on CNBC as an aged drug, and they expresses concern over AHP's pipeline. If WLA is in control on this deal, they may want to make an aggressive push for a replacement for Premarin. If DRMD at some point considers selling, Solvay was clearly the front runner but since DRMD is also cozy with WLA, could we see a bidding battle for Cenestin or DRMD? It could get interesting.